Table 2. Characteristics of the GWAS used in this study.
| Phenotype | Consortium | Sample size | Ancestry | Genotype data | PMID |
| Exposure (glycemic traits) | |||||
| Type 2 diabetes | DIAGRAM | Up to 212,747 individuals | European | GWAS array and metabochip array | 22885922, 28566273 |
| Fasting glucose | MAGIC | Up to 133,010 individuals | European | GWAS array and metabochip array | 22885924 |
| Fasting insulin | MAGIC | Up to 108,557 individuals | European | GWAS array and metabochip array | 22885924 |
| HbA1c | MAGIC | Up to 123,491 individuals | European | GWAS array | 28898252 |
| HOMA-β | MAGIC | Up to 98,372 individuals | European | GWAS array | 20081858 |
| HOMA-IR | MAGIC | Up to 94,636 individuals | European | GWAS array | 20081858 |
| Outcomes | |||||
| Alzheimer’s disease | IGAP | Up to 54,162 individuals | European | GWAS array | 24162737 |
HbA1c, hemoglobin A1c; HOMA-β, homeostasis model assessment -β-cell function; HOMA-IR, homeostasis model assessment -insulin resistance.